- Press Releases
- Events & Presentations
- Corporate Governance
- Shareholder & Stock Info
- Financial Reports
- Financial calendar
- SECURED RIGHTS ISSUE 2017
The members of the nomination committee shall, irrespective of how they are appointed, attend to the interests of all shareholders. The annual general meeting resolves how the nomination shall be appointed.
Nomination Committee of the Annual General Meeting 2018
In accordance with the principles of appointing the nomination committee, adopted by the annual general meeting of 26 April 2017, the chairman of the board of directors has contacted the major shareholders in order to appoint a nomination committee. The nomination committee of Immunicum consist of the four members appointed by the four largest shareholders that have accepted the invitation to participate in the nomination committee.
The nomination committee before the annual general meeting of 2018 is convened by the chairman of Immunicum’s board of directors Agneta Edberg and consists of Evert Carlsson (appointed by Swedbank Robur Fonder), Martin Lindström (appointed by Loggen Invest AB), Bengt Andersson (appointed by Bengt Andersson) and Mats Dahlgren (appointed by Mats Dahlgren). The nomination committee’s assignment is to prepare the following proposals to the annual general meeting of 2018: (i) proposal of nomination of the chairman of the annual general meeting; (ii) proposal of nomination of board members; (iii) proposal of nomination of the chairman of the board of directors; (iv) proposal of the remuneration to the board of directors; (v) proposal of nomination of auditors (if instructed pursuant to Chapter 8 Section 49 b Paragraph 2 of the Companies Act); (vi) proposal of remuneration to the auditors; and (vii) proposal of principles of the nomination committee before the annual general meeting of 2019.
The annual general meeting in Immunicum will be held on 25 April 2018.
Shareholders who wish to leave proposal to the nomination committee can do so by email to email@example.com or by letter to Immunicum AB (publ), Att: Valberedningen, Grafiska vägen 2, 412 63 Göteborg.